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Abstract
Background: Benign metastasizing leiomyoma (BML) is an orphan neoplasm commonly characterized by pulmonary
metastases consisting of smooth muscle cells. Patients with BML have usually a current or previous uterine leiomyoma,
which is therefore suggested to be the most probable source of this tumour. The purpose of this case report was to
determine the possible genetic grounds for pulmonary BML.
Case presentation: We present a case report in an asymptomatic 44-year-old female patient, who has developed
uterine leiomyoma with subsequent pulmonary BML. Whole exome sequencing (WES) was used to detect somatic
mutations in BML lesion. Somatic single nucleotide mutations were identified by comparing the WES data between
the pulmonary metastasis and blood sample of the same BML patient. One heterozygous somatic mutation was
selected for validation by Sanger sequencing. Clonality of the pulmonary metastasis and uterine leiomyoma was
assessed by X-chromosome inactivation assay.
Conclusions: We describe a potentially deleterious somatic heterozygous mutation in bone morphogenetic protein 8B
(BMP8B) gene (c.1139A > G, Tyr380Cys) that was identified in the pulmonary metastasis and was absent from blood and
uterine leiomyoma, and may play a facilitating role in the metastasizing of BML. The clonality assay confirmed a skewed
pattern of X-chromosome inactivation, suggesting monoclonal origin of the pulmonary metastases.
Keywords: Benign metastasizing leiomyoma, BMP8B, Endometriosis, GnRH agonists, Pulmonary lesion, Somatic gene
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Background
Benign metastasizing leiomyoma (BML) is a rare condi-
tion that occurs mainly in premenopausal women [1]
and is characterized most commonly by pulmonary and
lymph node metastases consisting of mature smooth
muscle cells [2]. BML is usually associated with a
current or previous uterine leiomyoma, and based on
histological findings and positive staining for oestrogen
and progesterone receptors [3], uterine leiomyomas have
been proposed as the most probable source of this
disease. The lesions are slow-growing and usually the
disease has a favourable prognosis. However, there are
no standardized guideline-based treatments for BML
and surgical removal along with hormone therapy is the
most frequently used management [3, 4]. Although
uterine leiomyomas are the most probable source of the
metastases, the pathogenesis of BML has still remained
enigmatic. Among other theories, it has been suggested
that BML may emerge from lymphatic and hematological
spread of the uterine tissue or via coelomic metaplasia [5].
The origin of metastases from uterine tissues is supported
by molecular studies demonstrating the same clonal origin
of the metastases of BML and original uterine leiomyomas
[6–8]. Almost half of the uterine leiomyomas are cytoge-
netically abnormal and furthermore, they possess gene
mutations, with mediator complex subunit 12 as the most
frequently affected gene [9]. The occurrence of chromo-
somal aberrations in BML metastases has also been shown
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[10, 11]; however, only one study has explored single
nucleotide variations (SNVs) and short insertions/dele-
tions (indels) in metastases using massively parallel
sequencing of a panel of 409 cancer-related genes [8].
Here, we present the results of whole exome sequencing
(WES) of the BML metastasis from a 44-year-old female
patient, who had developed uterine leiomyoma with sub-
sequent pulmonary BML.
Case presentation
Caucasian female, at the age of 34, underwent abdominal
uterine myomectomy because of anaemia, but not all
nodules were removed. Six years later, she underwent
laparoscopy-assisted supracervical hysterectomy (the
weight of the uterus was 288 g) because of recurrent
anaemia and uterine leiomyomas. Pathohistologically, the
specimens presented as a uterine smooth muscle tumour
without evidence of malignancy. Three years later, at the
age of 43, laparoscopic salpingo-oophorectomy was
performed because of a 6-cm endometrioma in the right
ovary, and superficial endometriotic lesions on the left
ovary were coagulated. In the same year, during a routine
chest X-ray examination, multiple well-defined round
pulmonary nodules of various sizes up to 40 mm in
diameter were detected (Fig. 1a). After 1-year follow-up, a
high-resolution computed tomography (HRCT)-scan of
the chest confirmed the largest nodule of having a diam-
eter of 40 mm. Video-assisted thoracoscopic surgery of
the left lung with a biopsy was performed in November
2013. Immunohistochemistry (IHC) analysis of lung lesion
specimens revealed positive staining for oestrogen recep-
tor α, progesterone receptor, desmin and α-smooth
muscle actin (Fig. 2a-d), while staining for Ki67 revealed
low mitotic activity (< 1–5%). On the basis of pathohistol-
ogy and IHC signature, the diagnosis of BML was estab-
lished, and subsequently, the patient received a treatment
with gonadotropin-releasing hormone (GnRH) agonist,
goserelin (Zoladex, AstraZeneca UK Ltd. London, UK),
for 6 months. The 4-month and 6-month follow-up chest
X-ray showed that lesions, formerly undergoing progressive
enlargement, had remained unchanged (Fig. 3). However,
the treatment was discontinued because of the disagreeable
side effects (weight gain of > 10 kg, flushing and profuse
sweating), and dietary and lifestyle modifications to address
the overweight issue were suggested. After a 5-month
treatment-free period (in January 2015), a new chest X-ray
examination revealed enlargement of the metastases (the
size of the largest nodule has increased by 4 mm reaching
44 mm, Fig. 1b) and the patient complained of shortness of
breath occurring more easily. Six months later, a new
HRCT-scan revealed further enlargement of the metastases
as the diameter of the largest lesion was 60 mm (Figs. 1c
and 3). The patient still decided to postpone the next treat-
ment because of the fear of the side-effects. After the
following 5 months (November 2015), additional enlarge-
ment of metastases was detected, with the largest lesion
gaining a diameter of 70 mm. The monitoring continued
without treatment as the patient reported her general
health and wellbeing to be satisfactory (presumably because
of the normalization of body weight), and refused from
GnRH agonist treatment. Seven months later, the follow-up
HRCT-scan showed the majority of the metastases had not
changed. In October 2016, the second 6-month treatment
with goserelin was initiated because of the further enlarge-
ment of some lesions, and the last chest X-ray in January
2017 showed stabilization of the size of majority of the
lesions; moreover, the largest nodules had decreased by
about 10% in size. The patient had no complaints except
for weight regain.
During the visits to the pulmonologist, several func-
tional tests were performed (Fig. 3). The values for
diffusing capacity of the lungs for carbon monoxide
(DLCO) were either within the normal range or
slightly below the lower limit of normal (normal de-
fined as 74% of the predicted value [12]), being in the
range of 69.6–86.8% predicted. Post-bronchodilator
forced vital capacity (FVC) values were below the
lower limit of normal (defined as 80% of the
predicted value for the patient), being 55.0–69.0%
predicted. Patient’s 6-min walk test (6MWT) results
a cb
Fig. 1 X-ray (a) and high resolution computed tomography (b, c) images of the BML patient from different examinations (November 2013, January
2015 and June 2015, respectively). Pulmonary metastases are shown by arrows
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were within the normal range, with absolute values of
the 6-min walk distance (6MWD) being 520–570 m
(100–139% of the predicted lower limit of normal
values), accompanied with mild breathlessness during
the 6MWT, but following by an adequate recovery.
The values of oxygen saturation measured by pulse
oximetry (SpO2) during the 6MWT were 90–97%, i.e.
normal or slightly below the lower limit of normal
(94%), with only one exceptional registered value indi-
cative of desaturation (81%).
Fig. 2 Immunohistochemistry of the BML patient’s lung metastasis showing positivity for oestrogen receptor α (a), progesterone receptor (b),
desmin (c) and α-smooth muscle actin (d). Original magnifications × 100
Fig. 3 The dynamics of pulmonary function parameters and the size of the largest lung metastasis of the BML patient. The size of the largest
lung metastasis is given in mm’s (left side Y-axis), diffusing capacity of the lungs for carbon monoxide (DLCO) and post-bronchodilator forced vital
capacity (FVC) are given as % predicted (left side Y-axis), the six-minute walk distances (6MWD) are given in meters (right side Y-axis), and the
lowest oxygen saturation (SpO2) during the six-minute walk test is shown as % (left side Y-axis) of the lower limit of normal. VATS - video-assisted
thoracoscopic surgery
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To find possible genetic causes of BML, WES of blood
and pulmonary metastasis was performed (detailed de-
scription of the WES is given in Additional file 1).
The mean sequencing depth was 57× for both DNA
samples. The manual inspection of the metastasis and
peripheral blood sample data did not reveal regions with
aberrant sequencing coverage, suggesting that no large
chromosomal alterations (deletions or duplications) were
present in the coding areas. After filtering the exome
data to exclude germline variants, a total of 121 poten-
tial somatic mutations (SNVs and short indels) affecting
109 genes (Additional file 2) were identified from the
protein-coding gene regions of DNA from the pulmon-
ary metastasis. The discovered somatic variants were
manually inspected and the candidate mutations were
filtered according to the following criteria: (1) mutations
in splice regions, and coding exons that affect amino
acids; (2) predicted deleterious by SIFT or PolyPhen2;
(3) as the pulmonary metastasis was histologically esti-
mated to consist almost entirely of smooth muscle cells
(> 90%) then in case of heterozygous mutations, similar
allelic depths for the reference and alternative allele were
expected; and (4) reported or suggested to be involved
in tumorigenesis. After rigorous filtering, one heterozy-
gous mutation in the BMP8B (bone morphogenetic pro-
tein 8B) gene was found to correspond to the filtering
criteria. The sequencing depths of the alternative and
reference alleles for BML and germline/blood DNA were
57/60 and 0/97, respectively. PolyPhen 2 and SIFT
predicted this variant as probably damaging (score 0.994)
and deleterious, respectively. Sanger sequencing con-
firmed the presence of an amino acid-affecting heterozy-
gous mutation (c.1139A > G, Y380C) in the seventh exon
of the BMP8B gene in the pulmonary metastasis (Fig. 4).
The tissue specimens of endometrioma and leiomyoma
from the same patient were also examined for this vari-
ation, but neither of the tissues had this mutation.
The human androgen receptor (AR) based X-
chromosome inactivation assay (HUMARA) was used
(as described elsewhere [13]) to determine the clonality
status of the pulmonary metastasis and the uterine leio-
myoma. Analysis of both of these specimens revealed a
similar pattern of skewed X-chromosome inactivation,
with an inactivation of the chromosome carrying the
shorter AR allele (Fig. 4 and Additional file 3). On the
contrary, the blood DNA demonstrated a random inacti-
vation of X-chromosomes.
Discussion and conclusions
We describe WES results of the patient, who has devel-
oped uterine leiomyoma with subsequent pulmonary
BML. In addition, the patient suffered from endometri-
osis presenting as a large endometrioma of the right
ovary and superficial lesions on the left ovary. The
Fig. 4 Validation of mutation in the BMP8B gene by Sanger sequencing and X-chromosome inactivation assay (HUMARA) of pulmonary metastasis and
peripheral blood of the BML patient. HpaII+ denotes enzyme-digested DNA and HpaII−means undigested DNA. Pulmonary metastasis demonstrates a
pattern of nonrandom X-chromosome inactivation with a nearly complete absence of the androgen receptor longer allele after HpaII digestion. The DNA
sequence electropherogram shows the reverse strand of the BMP8B gene
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mechanisms used to explain the pathogenesis of endomet-
riosis [14, 15] can also apply to BML. Hence, it has been
proposed that BML may evolve from lymphatic and
hematological spread, coelomic metaplasia and intraperi-
toneal seeding from ruptured leiomyoma [16]. Further-
more, there is an evidence from molecular studies
supporting the hypothesis that leiomyoma could be the
source of this benign tumour, as X-chromosome inactiva-
tion assay has confirmed the clonal origin of uterine
tumours and BML [6, 7, 17]. A very recent study that
showed shared SNVs between synchronous pulmonary
and uterine leiomyomata gives further strong evidence to
support a clonal relationship between these two tumours
[8]. Copy number variance (CNV) analysis has also been
used to explore the origin of metastases and in some
cases, similar chromosomal aberrations have been found
in tumours of both locations, confirming their genetic
relationship [10, 18]. In addition, the presence of consist-
ent chromosomal deletions of 19q and 22q in all five
investigated BML cases was demonstrated by Nucci et al.
[11]. However, these deletions are not characteristic to
rearrangements frequently found in uterine leiomyomas,
with chromosomes 6, 7, 10 and 12 most commonly
affected [19], and the authors proposed that BML may
arise from a biologically distinct minority of uterine leio-
myomas with an innate metastatic potential [11]. How-
ever, in some cases, CNV analysis showed balanced
karyotype of BML specimens without any changes in
DNA copy numbers [6, 17], as was also the case for the
patient described in the current study.
Most of BML cases have been detected on routine
chest X-rays. BML is a rare condition that should always
be considered in case of incidental lung findings in
women with a previous or coincident history of uterine
leiomyoma. The presence of oestrogen and progesterone
receptors supports a connection between BML and
female reproductive tract and makes the basis for the
rationale for using hormonal treatment [5, 20]. GnRH
agonists are often used and are described to give
favourable therapeutic outcomes in terms of preventing
the enlargement of nodules [21]. According to the pub-
lished data, the periods of GnRH agonist treatment vary
from 3 to 42 months [22, 23]. In the current case, we
had a unique opportunity to longitudinally observe the
growth dynamics of the pulmonary metastases, which
followed the pattern of goserelin treatment. The enlarge-
ment of metastases, when patient discontinued the treat-
ment because of the unfavourable side effects, provided
the rationale for continuing the hormone therapy.
According to our knowledge, this is the first study using
WES to explore SNVs of BML specimen. Even though
WES revealed several somatic candidate-mutations in the
pulmonary BML tissue, only a heterozygous mutation in
the BMP8B gene corresponded to the criteria we used to
select the probable disease-associated mutations. Wu et
al. used the Ion AmpliSeq Comprehensive Cancer Panel
that targets the exons of 409 tumor suppressor genes and
oncogenes to find possible mutations in three cases of
synchronous pulmonary and uterine leiomyomata tissues
[8]. Somatic mutations were found in all investigated
tissues, and shared alterations between uterine leiomyoma
and pulmonary metastases were found in two out of three
cases, but no recurrent mutations were observed. The
authors concluded that the probability of finding the same
alterations in different cases was very low as none of the
detected mutations has commonly been described in
leiomyomas. Unfortunately, as the BMP8B gene is not a
common cancer-gene, it is also not included in the Cancer
Panel and therefore the presence or absence of mutations
in this gene could not be evaluated in the study by Wu
and colleagues. BMPs represent a family of signalling
molecules that belong to the transforming growth factor-β
superfamily of proteins and play crucial roles in all organ
systems [24]. In cancer, BMPs can either suppress or
promote tumorigenesis and are involved in the metastasis
of cancer cells [25]. BMP8B is a gene encoding a protein
with a role in spermatogenesis [26] and in thermogenesis
[27]. BMP8B has not been detected as a mutational cancer
driver; however, there are some reports describing altered
expression of the BMP8B gene in cancers [28–30].
Reduced BMP8B mRNA expression has been detected in
tumour tissues compared to adjacent normal tissues,
whereas experimental induction of the BMP8B overex-
pression inhibited cell growth [29], proposing that BMP8B
could act as a tumour suppressor gene [28]. This gene
locates on the short arm of chromosome 1 and the muta-
tion detected in pulmonary metastasis locates in the last
(seventh) exon of the gene. The mutation affects amino
acid constitution of the protein (tyrosine-to-cysteine
substitution) and because both PolyPhen2 and SIFT anno-
tate it as probably damaging, we can speculate that it plays
a role in BML lesions’ growth and metastasis. Unfortu-
nately, we had no possibility to test the impact of the
mutation on protein function level as we had only limited
FFPE material of pulmonary metastasis. The same muta-
tion was not present in the leiomyoma tissue of the
patient; and therefore, we can assume that a) the mutation
has occurred in the lung BML lesion only; b) the patient
suffered from multiple leiomyomas, and the pulmonary
BML did not arise from that particular uterine leiomyoma
tissue analysed in the current study; or c) BML does not
originate from leiomyoma. It has been demonstrated that
leiomyomas develop as clonal lesions but multiple nodules
in a single uterus may have different clonal origin [31] and
harbour different chromosomal aberrations [32]. Also, the
study by Wu et al. revealed shared somatic mutations only
in two out of three pairs of uterine leiomyoma and BML
metastases [8]. Our clonality analysis confirmed the non-
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random X-chromosome inactivation in both uterine leio-
myoma and pulmonary metastasis, with the same allele
being inactivated. However, this finding can also be coinci-
dental showing just the clonal origin of these tumours.
In addition to leiomyoma, the patient suffered from
endometriosis that resulted in the development of a large
ovarian endometrioma. According to the theories of endo-
metriosis development, endometrial tissue is the most
probable source of endometriosis. Therefore, we examined
the endometrioma specimen for the presence of the
BMP8B gene mutation, but the analysis revealed only a
wild-type allele. Thus, the co-occurrence of endometriosis
and BML in the current patient is probably random, as
previously only a few reports have described BML-
associated endometriosis [33, 34].
In conclusion, we described the longitudinal follow-up
of a patient suffering from BML. We demonstrated that
GnRH agonist therapy gave favourable outcome and treat-
ment discontinuation caused enlargement of the lung
lesions. Genetic analysis revealed a BMP8B gene mutation
in the lung lesion; however, the link between mutations in
the BMP8B gene and pulmonary BML needs to be corrob-
orated by further studies involving additional patients and
exploring the functional consequences of the here-
described mutation.
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